Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations

Objective: The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is p...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2016

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23941

Acceso en línea:

https://doi.org/10.1089/aid.2015.0095
https://repository.urosario.edu.co/handle/10336/23941

Palabra clave:

Rilpivirine
Anti human immunodeficiency virus agent
Rilpivirine
Rna directed dna polymerase inhibitor
Antiviral resistance
Antiviral susceptibility
Article
Belgium
Epidemic
Founder effect
Genotype
Geographic distribution
Human
Human immunodeficiency virus 1
Human immunodeficiency virus 1 infection
Human immunodeficiency virus infected patient
Major clinical study
Nonhuman
Observational study
Portugal
Prevalence
Priority journal
Resistance associated mutation
Retrospective study
Tablet
Virus mutation
Virus resistance
Drug effects
Genetics
Highly active antiretroviral therapy
Hiv infections
Mutation
Procedures
Single nucleotide polymorphism
Anti-hiv agents
Belgium
Founder effect
Genotype
Hiv infections
Hiv-1
Humans
Mutation
Portugal
Retrospective studies
Reverse transcriptase inhibitors
Rilpivirine
viral
single nucleotide
highly active
Antiretroviral therapy
Drug resistance
Polymorphism

Rights

License

Abierto (Texto Completo)